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Vasopressin regulates the growth of the biliary
epithelium in polycystic liver disease
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Luigi Pannarale1, Francesca Olivero1, Guido Carpino1, Gianfranco Alpini3,4,5, Paolo Onori1 and Eugenio Gaudio1
The neurohypophysial hormone arginine vasopressin (AVP) acts by three distinct receptor subtypes: V1a, V1b, and V2.
In the liver, AVP is involved in ureogenesis, glycogenolysis, neoglucogenesis and regeneration. No data exist about the
presence of AVP in the biliary epithelium. Cholangiocytes are the target cells in a number of animal models of cholestasis,
including bile duct ligation (BDL), and in several human pathologies, such as polycystic liver disease characterized by
the presence of cysts that bud from the biliary epithelium. In vivo, liver fragments from normal and BDL mice and rats
as well as liver samples from normal and ADPKD patients were collected to evaluate: (i) intrahepatic bile duct mass
by immunohistochemistry for cytokeratin-19; and (ii) expression of V1a, V1b and V2 by immunohistochemistry,
immunofluorescence and real-time PCR. In vitro, small and large mouse cholangiocytes, H69 (non-malignant human
cholangiocytes) and LCDE (human cholangiocytes from the cystic epithelium) were stimulated with vasopressin in the
absence/presence of AVP antagonists such as OPC-31260 and Tolvaptan, before assessing cellular growth by MTT assay
and cAMP levels. Cholangiocytes express V2 receptor that was upregulated following BDL and in ADPKD liver samples.
Administration of AVP increased proliferation and cAMP levels of small cholangiocytes and LCDE cells. We found no effect
in the proliferation of large mouse cholangiocytes and H69 cells. Increases were blocked by preincubation with the
AVP antagonists. These results showed that AVP and its receptors may be important in the modulation of the proliferation
rate of the biliary epithelium.
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Arginine vasopressin,1 also known as antidiuretic hormone,1
is a neurohypophysial hormone having multiple functions,
including renal water reabsorption, cardiovascular home-
ostasis and hormone secretion from the anterior pituitary.2,3
AVP is produced by neurons in the paraventricular and
supraoptic nuclei of the hypothalamus.4,5 The hormone is
released upon an increase in extracellular fluid osmolarity or a
decrease in blood pressure and acts on target organs through
several receptors: V1a, V1b and V2, that are expressed in
different target organs and mediate distinct effects.4 V1a is
expressed predominantly in the walls of arteries, arterioles
and veins and mediates vasoconstriction. It also increases
renin production by acting on renal granule cells, indirectly
increasing angiotensin II and aldosterone.6 V1b (or V3) is
expressed by anterior pituitary cells and stimulates the release
of adreno cortico tropic hormone.7 V1a and V1b are also
expressed by chromaffin cells of the adrenal medulla where
they stimulate catecholamine secretion.8 V2 is found in the
distal tubules and collecting ducts of the kidneys and mediates
water reabsorption.9 The three AVP receptors are G-protein
coupled receptors. Upon ligand binding, the cellular levels
of second messengers (such as cAMP, Ca2+, inositol 1,4,5-
triphosphate and diacylglycerol) increase.10 V2 receptor is
associated with a Gs protein and, upon activation, cAMP
levels increase; this causes the translocation of aquaporin2
and the amiloride-sensitive epithelial Na+ channel in the
principal cells of the collecting duct.11 In addition to
regulating water and electrolyte balance and vasoconstriction,
AVP also affects the promotion of cellular growth and
proliferation, lipid metabolism and protein turnover.12 Cell
proliferation and growth were observed in several types of
cells: fibroblasts, vascular endothelial and smooth muscle
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cells, cardiomyocytes, and also hepatocytes.13 Moreover, in
human pathology, vasopressin is also involved in autosomal-
dominant polycystic kidney disease (ADPKD), a condition
characterized by bilateral renal cysts, kidney pain, hyperten-
sion and progressive loss of renal function, owing to
mutations in plasma membrane-spanning polycystin 1 and
2 (PKD1 and PKD2, respectively) genes.14 In many patients
with ADPKD, there is the development of hepatic cysts, which
originate from cholangiocytes, the cells that form the biliary
epithelium, linked to the dysfunction of the primary
cilium.15–17 Primary cilia have been identified as key
organelles in the pathogenesis of ADPKD and related cystic
diseases.18 In the liver parenchyma, only cholangiocytes
possess primary cilia. They are regarded as the antennas of
a cell, involved in mechano-, osmo-, and chemo-reception of
bile flow and composition.19 The ciliary compartment is also
the active site of the protein products of hepatocystic disease
genes, such as PKD1 and PKD2.18 Liver cysts are usually
asymptomatic, but the progressive growth may cause dyspnea,
gastroesophageal reflux and nausea and mechanical low back
pain arise because of the mass effect of the polycystic liver.20
Recently, the somatostatin analogs lanreotide and octreotide
plus mTOR inhibitors have represented promising new
agents for the treatment of patients with PLD.21,22 These
agents reduce intracellular levels of cAMP by activating
signaling cascades through the Giα subunit, thereby prevent-
ing accumulation of fluid in liver cysts.23 AVP has a role
in the pathogenesis of renal cysts in ADPKD, stimulating the
cyst growth in several rodent models and in cultured human
cells.24 Currently, there are no data on the effects of
vasopressin and its receptor antagonists in the growth of
hepatic cysts during PLD. For this reason, our aim has been to
evaluate the role and the effect of the hormone in the growth
of the biliary epithelium.
MATERIALS AND METHODS
Materials
All reagents were purchased from Sigma-Aldrich (St Louis,
MO, USA) unless otherwise indicated. The V2 primers for
real-time PCR were purchased from SABiosciences (Freder-
ick, MD, USA). The RNeasy Mini Kit to purify total
cholangiocyte RNA was purchased from Qiagen (Valencia,
CA, USA). The EIA kits for assessing cell proliferation were
purchased from Cayman Chemical (Ann Arbor, MI). All the
antibodies were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA) or Sigma-Aldrich.
Rat and Mouse Liver Samples
Male Fischer 344 rats and male C57BL/6 mice were purchased
from Charles River (Wilmington, MA, USA), maintained in a
temperature-controlled environment (20–22 °C) with a 12-h
light–dark cycle and fed ad libitum standard chow. Animals
had free access to drinking water. Our studies were carried
out in normal and 1-week bile duct ligated (BDL) rats or
mice.25 Before each experimental procedure, the animals were
anesthetized by sodium pentobarbital (50 mg/kg body wt i.p.)
following the regulations of the panel on euthanasia of the
American Veterinarian Medical Association and local autho-
rities. All protocols were approved by the Institutional Animal
Care and Use Committee of Baylor Scott & White, Temple,
TX, USA.
Human Liver Samples
We studied eight liver specimens obtained for diagnostic
purposes at surgery with a diagnosis of ADPKD. Liver cysts
were subdivided on the basis of their size as large (43 cm
maximum diameter) or small cysts (o3 cm maximum
diameter). As controls, we evaluated liver biopsies with a
normal histology from patients submitted to laparotomy
(four fragments). The procedures followed for this study were
in accordance with the institutional committee and abided by
the ethical guidelines of the 1975 Declaration of Helsinki.
Immunohistochemistry
Immunohistochemistry was performed in 3-μm sections from
liver fragments of rat, mouse and human. Sections were
deparaffinized, then hydrated and rinsed in 1 × phosphate-
buffered saline (PBS, pH 7.4) before applying the selected
primary antibody. Sections were incubated overnight at
4 °C with polyclonal antibodies for V1a (SAB2501519,
Sigma-Aldrich), V1b (HPA017337, Sigma-Aldrich) and V2
(sc-18101, Santa Cruz Biotechnology). The following day,
samples were rinsed with PBS, incubated with secondary
biotinylated antibody (LSAB Plus System; Dako, Milan, Italy),
then with Dako ABC (LSAB Plus system), and finally deve-
loped with 3,3′-diaminobenzidine. To confirm the specificity
of immunoreaction, negative controls were performed for all
immunoreactions. Sections were examined with a Leica
Microsystems DM 4500 B Microscopy equipped with a
JenoptikProg Res C10 Plus Videocam. Observations were
processed with an Image Analysis System (IAS; Delta Sistemi)
and were independently performed by two researchers in a
blinded manner.
Immunofluorescence
In vitro studies were performed using the mouse and human
cell lines and normal and BDL rat cholangiocytes isolated
from the experimental samples. We also used our immorta-
lized murine cell lines of small and large cholangiocytes.26,27
The cells were maintained in a specific medium. A human
immortalized non-malignant cholangiocyte cell line (H69, a
gift of Dr Gregory Gores, Mayo Clinic, Rochester, MN, USA)
and an immortalized cell line obtained from the epithelium
lining the hepatic cysts from patients with ADPKD (LCDE or
CL3, a gift of Dr Douglas Jefferson, Tufts Medical School,
Boston, MA, USA)16 were also used. Cholangiocytes from cell
lines were seeded on coverslip in a six-well plate and allowed
to adhere overnight. Cells were fixed in 4% paraformalde-
hyde, and following washes and incubation in 4% bovine
serum albumin (BSA) and PBS-T, they were incubated with
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the selected primary antibody (V1a, V1b, V2). Then the cells
were washed in PBS-T and then placed in the specific Alexa
Fluor 488 secondary antibody in a dark room. Finally,
cholangiocytes were rinsed and the coverslip was put onto
slide with a drop of DAPI.
Real-Time PCR
To evaluate the messenger expression of V2 in purified mouse
(normal and BDL) and human (normal and ADPKD)
cholangiocytes, we used the RT2 Real-Time assay from
SABiosciences as described.26 A ΔΔCT (delta delta of the
threshold cycle) analysis was performed using normal
cholangiocytes as the control sample. The primer for V2
(purchased from SABiosciences) was designed according to
the NCBI GenBank Accession number NM_001146151.1.1
Data were expressed as relative mRNA levels± s.e.
Proliferation Assay and cAMP Levels
H69 and LCDE following culture in the appropriate medium
were deprived of serum for 24 h. Cells were then maintained
in serum-deprived conditions for an additional 24 h for
MTT proliferation assay (controls) or exposed to serum,
AVP (from 0.1 to 100 μg/ml). Except for large mouse
cholangiocytes, we also performed preincubation with or
without Tolvaptan (100 μg),28 a V1a, V1b or V2 antagonist or
OPC-31260, a specific V2 antagonist (100 μg).29 In detail, cell
medium was replaced with a fresh serum-free medium with
the tested agent. We used a commercially available colori-
metric cell proliferation assay (CellTiter 96 aqueous non-
radioactive cell proliferation assay, MTT Kit), following the
manufacturer’s instructions. Proliferation index was calcu-
lated as the ratio between cell numbers in both unstimulated
and stimulated cultures.
The levels of cAMP, a functional parameter of cholangio-
cyte growth,30 were measured using EIA kits, purchased from
Cayman Chemical. cAMP was determined in supernatants
from small and large mouse cholangiocytes, H69 or LCDE
treated with/without AVP in absence/presence of the two
inhibitors (Tolvaptan and OPC-31260) according to the
manufacture’s protocol.
Statistical Analysis
Data are presented as arithmetic mean± s.d. Student’s t-test
or Mann–Whitney U-test was used to determine differences
between groups for normally or not normally distri-
buted data, respectively. A P-value of o0.05 was considered
statistically significant. Statistical analyses were performed
using the SPSS statistical software.
RESULTS
Cholangiocytes Express the V2 Receptor
Rat
Immunohistochemistry performed on the rat livers showed
that V1a and V1b expression in cholangiocytes is negligible in
both normal and BLD rats, whereas V2 receptor is expressed
in normal rat cholangiocytes and markedly expressed in BDL
rat cholangiocytes (Figure 1a). Similarly, immunofluores-
cence confirmed that rat cholangiocytes express V2 in both
cell lines, with the latter having an increased expression of the
receptor. V1a and V1b were not expressed in both cell types
(Figure 2a).
Mouse
Immunohistochemistry performed in the normal mouse
livers showed that normal small and large cholangiocytes
express V2 receptor, whereas V1a and V1b were not present.
In BDL mice, the expression of V2 was significantly increased,
whereas V1a and V1b expression remained negligible in BDL
mice (Figure 1b). In vitro, small and large mouse cholangio-
cytes express V2 receptor. V1a and V1b are not expressed
both in small and large cholangiocytes (Figure 2b). V2
receptor expression in cholangiocytes was confirmed by
analyzing gene expression for this receptor in isolated
cholangiocytes from both Sham and BDL mice. The latter
were shown to have a doubled V2 receptor expression with
respect to the Sham mice by real-time PCR (Figure 3a).
Human
The results obtained in mice and rats were confirmed in
human samples. V1a and V1b were not expressed in the
normal livers as well as hepatic cysts obtained from ADPKD
patients, except for a slight positivity of V1b in the cystic
epithelium. On the other hand, V2 was expressed by
cholangiocytes in the normal livers; its expression was
significantly increased in cholangiocytes lining hepatic cysts
obtained from ADPKD patients (Figure 1c). In vitro, in
human H69 cells the V2 receptor was shown to be expressed,
whereas V1a and V1b were not present (Figure 2c). In LCDE
cells, the expression of V1a was negative and V1b was weakly
represented, whereas V2 was significantly increased above its
normal expression level. In addition, V2 receptor gene
expression was confirmed both in H69 and LCDE cells and
was higher in LCDE cells when compared with H69
(Figure 3b).
Measurement of Cholangiocyte Proliferation
Mouse
To verify whether vasopressin has a different role in mature
and immature cholangiocytes, we studied its effects on small
and large cholangiocyte growth. The MTT proliferation assay
yielded different results in mouse small and large cholangio-
cytes. By increasing the amount of vasopressin provided to
the small cholangiocyte cell lines, a concomitant proliferation
was observed. At 0.1 μg, proliferation was 1.5 the normal, it
doubled at 1 μg, then increased to 2.5 times than normal at
10 μg, and tripled at 100 μg. No effects on proliferation were
observed in large cholangiocytes treated with vasopressin
(Figure 4a). The administration of Tolvaptan or OPC-31260,
V2 antagonists,31,32 to small cholangiocytes decreased the
proliferative rate of these cells (Figure 4b).
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Human
MTT proliferation assay in H69 also yielded a slight increase
in proliferation up to 1.01 at 1 μg, 1.02 at 10 μg and 1.03 at
100 μg. Proliferation was not observed upon administering
100 μg vasopressin in combination with Tolvaptan or 100 μg
vasopressin with OPC-31260 (Figure 4c). The same results
were seen in LCDE cells, but the effect of vasopressin on
proliferation was much more striking: at 1 μg vasopressin
proliferation was higher compared with the corresponding
H69 value. Instead, when administering 100 μg vasopressin
with Tolvaptan or 100 μg vasopressin with OPC-31260, there
was no proliferation detectable (Figure 4c).
Measurement of Intracellular Levels of cAMP
Similar to that shown for secretin, we found in small mouse
cholangiocytes that vasopressin increases cAMP levels, an
increase that was prevented by preincubation with Tolvaptan
or OPC-31260 (Figure 5a). Likewise, we have evaluated the
effect of vasopressin and its receptor antagonists in human
cell lines, and the intracellular vasopressin-stimulated cAMP
levels as well as cholangiocyte proliferation increased, an
enhancement blocked by preincubation with the two V2
receptor antagonists, Tolvaptan and OPC-31260 (Figure 5b).
This supports the concept that vasopressin, both in mouse
and human, sustains biliary growth via a cAMP-dependent
signaling pathway.
DISCUSSION
The present study provides the following new findings: (i)
mouse, rat and human cholangiocytes express V2 receptors
that are upregulated following BDL as well as in cholangio-
cytes lining liver cysts in ADPKD patients; (ii) in vitro, the
administration of vasopressin increased proliferation and
cAMP levels of small mouse cholangiocytes and human LCDE
cells, these effects were blocked by preincubation with
Tolvaptan as well as OPC-31260, a specific V2 antagonist;
and (iii) vasopressin does not induce significant changes in
proliferation of large mouse cholangiocytes.
Cholangiocytes are characterized by marked proliferative
capacities that are evident under different experimental
Figure 1 Representative immunohistochemistry for the three AVP receptors: V1a, V1b, and V2 in liver sections from Normal and BDL-1week rats
(a), from Normal and BDL-1week mice (b), and from Normal and PLD human samples (c). Bile ducts express V2 subtype of vasopressin receptors in
Normal animals and, with higher levels, in the experimental model of BDL, both in mouse and rat. In human samples, V2 is present in normal biliary
epithelium and increases during PLD, both in small (diameter o3 mm) and large (diameter 43 mm) cysts. No or very low staining was visible in
the immunohistochemistry for V1a and V1b. No staining was visible when primary antibodies were replaced with non-immune serum, original
magnification, × 40.
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conditions, such as BDL in mouse or rat models.17,33,34 These
conditions mimic human chronic liver diseases, including
primary biliary cirrhosis and polycystic liver disease, where
the cholangiocytes represent the target of the disease.35,36 In
particular, mutations in polycystins (PC1 or PC2) are a cause
of polycystic liver disease, characterized by the progressive
Figure 2 By immunofluorescence, cholangiocytes from Normal and BDL rats (a) express V2 receptor subtype. After BDL, cells present low expression of
V1a and V1b but higher immunopositivity for V2. The same experiments were performed in small and large cholangiocytes from mice (b), where the
expression of V2 is predominant both in small and large cells. Finally, in human cholangiocytes (c), the immunofluorescence demonstrated that they
express V2 with greater amount in LCDE, the cells from the cystic epithelium. Specific immunoreactivity of representative fields is shown in green; cell
nuclei were stained with DAPI (blue). No staining was visible when primary antibodies were replaced with non-immune serum (data not shown).
Bar = 200 μm.
Figure 3 Evaluation of the mRNA by real-time PCR in purified cholangiocytes from (1) normal and BDL-1 week mouse; *Po0.05 vs sham cells (a) and
(2) H69 and LCDE; *Po0.05 vs H69 cells (b). Murine and human cholangiocytes express V2 mRNA. The expression of V2 was significantly increased in
cholangiocytes from BDL mice compared with normal mice (a). As well as in LCDE cells compared with H69 cells (b). Data are mean± s.e.m. of three
PCR reactions.
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development of multiple cysts that initially bud from the
biliary epithelium with progressive lack of communication with
the biliary tree.20,37 A higher production of cAMP represents
the main signaling abnormality of cystic cholangiocytes that is
responsible for the proliferative activity of cystic epithelium.38
In fact, studies in PC2-defective cholangiocytes have shown
that both ERK1/2 and mTOR converge in stimulating cyclins
and HIF1α-dependent VEGF-A secretion.39
The hormone vasopressin acts on different receptors, such
as V1a, V1b and V2, but the binding with V2 is the main
hormonal regulator of adenylyl cyclase activity in freshly
dissected collecting ducts.40 The V2-induced effects on cAMP
and water permeability may be limited by the action of AVP
on V1a receptors stimulating phospholipase C, phosphoino-
sitide hydrolysis and Ca2+ release from the endoplasmic
reticulum.41,42 Recent experimental studies have suggested a
central role for vasopressin and 3′-5′-cyclic adenosine
monophosphate in promoting cyst growth, kidney enlarge-
ment and renal function decline in ADPKD.43 Inhibition of
vasopressin by either a pharmacological agent such as
vasopressin V2 receptor antagonist (V2RA)44,45 or drinking
more water led to reduced growth of cysts and renal function
preservation in animal models of polycystic kidney disease.46
In turn, the increased production of cAMP stimulates
proliferation and growth of ADPKD cells and drives Cl−
and fluid secretion via protein kinase A-stimulated CFTR.47
Furthermore, the arginine vasopressin V2 receptor antago-
nists OPC-31260 and Tolvaptan inhibit the development of
polycystic kidney disease in cpk mice and in three animal
orthologs to human autosomal-recessive polycystic kidney
Figure 4 Evaluation of cholangiocyte proliferation with the administration of vasopressin (0.1–100 μg/ml) at different concentrations for 24 h by MTT
assay in mice small and large cholangiocytes (a); in small cholangiocytes with the preincubation with two V2 antagonists: Tolvaptan and OPC-31260 (b);
and in H69 and LCDE (c). Vasopressin increased growth of small cholangiocytes, H69 and LCDE in a dose-dependent manner, while large cholangiocytes
are not sensitive to these concentrations of the hormone. The proliferation was also partly inhibited by the two V2 antagonists. *Po0.05 vs basal
treatment, #Po0.05 vs AVP 100 μg treatment. Data are means ± s.e. of five experiments.
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disease (PCK rat), autosomal-dominant polycystic kidney
disease (Pkd2− /WS25 mice) and nephronophthisis (pcy
mouse) by downregulating cAMP signaling, cell prolife-
ration and chloride-driven fluid secretion.44,45,48,49 Instead,
the V2 receptor agonist 1-deamino-8-d-arginine vasopressin
increased renal cAMP and recovered the full cystic phenotype
and aggravated the renal cystic disease.45,50 Our study has
demonstrated that the receptor V2 is also expressed in
cholangiocytes and this expression increases in the experi-
mental model of mouse and rat BDL and in the human biliary
epithelium that lines the hepatic cysts. In addition, the in vitro
data have showed a proproliferative effect of vasopressin
in small cholangiocytes, which represents the immature
biliary compartment, activated to compensate for the damage
of large cholangiocyte.51 In vitro, small and large mouse
cholangiocytes express V2 receptor, while V1a and V1b are
not expressed both in small and large cholangiocytes.
Subsequently, we have analyzed cholangiocyte proliferation
after AVP treatment in the same types of cells by MTT to
demonstrate that small cholangiocytes significantly enhance
Figure 5 Intracellular cAMP levels were measured in: (a) small (white bar) and large cholangiocytes (black bar) and (b) also in H69 (white bar) and in
LCDE (black bar) treated with 0.2% BSA (basal) vasopressin (100 μg/ml) in the absence or presence of Tolvaptan (100 μg) or OPC-31260 (100 μg).
Vasopressin significantly increased the intracellular levels of cAMP mainly in small cholangiocytes, H69 and LCDE. Effects were blocked by preincubation
with the two inhibitors, Tolvaptan and OPC-31260. Data are expressed as mean ± s.d. of six experiments. *Po0.05 vs its corresponding basal value,
#Po0.05 vs its corresponding vasopressin treatment.
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their growth with vasopressin administration, whereas large
cells display no significant increase. The reason could be
linked, even if we did not perform analysis for that, to the
quantity of receptor (V2) expressed by the two different types
of cholangiocytes. Probably small cholangiocytes contain a
higher presence of V2 receptor that lead to increase more the
activation and production of cAMP. Instead, large cells may
express a small amount of receptors to partially block the
possibility to proliferate. Moreover, AVP enhances the growth
of the hepatic cystic epithelium by the activation of the cAMP
signaling pathway. These specific effects were blocked if we
used Tolvaptan and OPC-31260, which selectively antago-
nizes V2 receptors, with a reduced proliferation and a
decrease in cAMP levels. In fact, AVP exerts its effect by
binding to three types of receptors: V1a, V1b, and V2. These
receptors are G-protein-coupled with seven transmembrane
domains, but their roles, activation and regulation of mRNA
expression are very different. In a recent study of Tran et al, it
is reported that AVP increases intracellular Ca2+ in human
adipose-derived stromal/stem cells by activating V1a receptors
and the PLC–IP3 pathway. In contrast, mouse embryonic
stem cells express all three receptor subtypes with different
expression levels.52 Moreover, Gassanov’s group showed that
AVP facilitates cardiomyogenesis by activating NO signaling
via V2 receptor; however Ca2+ signaling was not discovered.
Whereas AVP, via the type 2 receptor (V2), activates the
cAMP/PKA/cAMP response element-binding protein path-
way.53 So the different expression and link with a receptor can
lead to a different activation pathway in several type of cells.
In our case, cholangiocytes express V2 and a cAMP-
dependent pathway is activated. Normally, large cholangio-
cytes are responsible for the majority of biliary fluid secretion,
through the activation of a cAMP-dependent pathway. In
small cholangiocytes, on the other hand, Ca2+-activated
signaling pathways seem predominant.26 Indeed, the activa-
tion of purinergic receptors in small and large cholangiocytes
induces Ca2+-dependent Cl− secretion via TMEM16A,
providing an alternative route to the secretin-stimulated
cAMP-dependent ductal fluid secretion. For these reasons, we
can speculate that, as small cholangiocytes express only
V2, the link of AVP with the receptor leads to the activation
of a cAMP-dependent signaling pathway in these immature
cells but that the stimulation with exogenous AVP may
induce and start a quick transformation in mature
cholangiocytes.
In summary, the results of this study indicate that AVP
is a modulator of cholangiocyte proliferation. Like in the
kidney also in the liver, cyst epithelial cells are persistently
stimulated to proliferate and secrete fluid; this may be further
enhanced by the renal and hepatic concentrating defect and
increased circulating levels of AVP that occur in PKD and
PLD. These observations could provide further support for
the management and the modulation of V2 receptor in the
regulation of the proliferation rate of the biliary epithelium
during PLD.
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